Doctors test hitting leukemia early in High-Risk patients

This study tested if starting a drug called ibrutinib earlier could better control a type of blood cancer called chronic lymphocytic leukemia (CLL) in patients who are at high risk for the disease getting worse but don't yet have symptoms. The usual approach is to wait until symptoms appear before treating. In this trial, 23 patients with high-risk CLL took ibrutinib daily for up to two years to see if this early treatment could improve outcomes compared to waiting.